“Life sciences tools and services firm Agilent Technologies outperformed as demand began to recover following an extended downturn in the industry after the COVID-19 pandemic and cuts to National Institutes of Health funding. Biotech funding and...”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.